Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients

被引：18
|
作者：
Calcagno, Andrea [1 ]
Simiele, Marco [1 ]
Motta, Ilaria [1 ]
Pinna, Simone Mornese [1 ]
Bertucci, Roberto [1 ]
D'Avolio, Antonio [1 ]
Di Perri, Giovanni [1 ]
Bonora, Stefano [1 ]
机构：
[1] Univ Turin, Dept Med Sci, Infect Dis Unit, Turin, Italy
来源：
AIDS RESEARCH AND HUMAN RETROVIRUSES | 2016年 / 32卷 / 05期
关键词：
ANTIRETROVIRAL THERAPY; PHARMACOKINETICS; ESCAPE;
D O I：
10.1089/aid.2015.0337
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：409 / 411
页数：3
相关论文
共 50 条
  • [1] Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV patients with renal impairment
    Post, F.
    Andrade-Villanueva, J.
    Fisher, M.
    Winston, J.
    Liu, Y.
    Zhong, L.
    Cheng, A.
    Rhee, M.
    Szwarcberg, J.
    HIV MEDICINE, 2014, 15 : 115 - 115
  • [2] Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults
    Bonora, Stefano
    Calcagno, Andrea
    Trentalange, Alice
    Di Perri, Giovanni
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (03) : 409 - 419
  • [3] Virological response to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients with lamivudine-resistant hepatitis B virus coinfection
    Huang, Y-S
    Chang, S-Y
    Sun, H-Y
    Su, Y-C
    Liu, W-C
    Hung, C-C
    HIV MEDICINE, 2019, 20 : 299 - 299
  • [4] Efficacy and safety of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients: real-world data
    Tabak, Fehmi
    Zerdali, Esra
    Altuntas, Ozlem
    Gunduz, Alper
    Bolukcu, Sibel
    Mete, Bilgul
    Nakir, Inci Y.
    Kumbasar Karaosmanoglu, Hayat
    Yildiz, Dilek S.
    Meric Koc, Meliha
    Dokmetas, Ilyas
    INTERNATIONAL JOURNAL OF STD & AIDS, 2021, 32 (06) : 562 - 569
  • [5] Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV
    Imaz, Arkaitz
    Podzamczer, Daniel
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2017, 15 (03) : 195 - 209
  • [6] Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
    Kuo, Po-Hsien
    Sun, Hsin-Yun
    Chuang, Yu-Chung
    Wu, Pei-Ying
    Liu, Wen-Chun
    Hung, Chien-Ching
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 92 : 71 - 77
  • [7] Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients
    Calcagno, Andrea
    Bonora, Stefano
    Bertucci, Roberto
    Lucchini, Anna
    D'Avolio, Antonio
    Di Perri, Giovanni
    AIDS, 2010, 24 (06) : 931 - 932
  • [8] Cobicistat/elvitegravir/emtricitabine/tenofovir-alafenamideRebound of HIV infection: case report
    Reactions Weekly, 2020, 1828 (1) : 155 - 155
  • [9] Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamideReduced susceptibility to elvitegravir : case report
    Reactions Weekly, 2016, 1617 (1) : 72 - 72
  • [10] Cutaneous adverse reactions associated with combination elvitegravir/cobicistat/emtricitabine/tenofovir tablets in patients with HIV
    Bruins, Finola M.
    Oyerinde, Oyetewa B.
    Posligua, Alba
    West, Dennis P.
    Nardone, Beatrice
    Rani, Monica
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB207 - AB207
12345